Viriom Inc - Company Information
Viriom inc. is a commercial and late development stage biotech company developing novel therapies and prevention treatments against hiv and hepatitis b virus (hbv). viriom's pipeline includes: elpida® (elsulfavirine), the best-in-class nnrti that received its first market authorization in 2017; fixed doze combinations with nucleoside reverse transcriptase inhibitors; an innovative extended release weekly oral formulation; and vm1500a - a long acting injectable therapy and pre-exposure prophylaxis. viriom is also developing a highly potent prodrug of the antiviral tenofovir (active component of both vemlidy® and viread®) to treat hiv and hepatitis b patients. viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of hiv and chronic hbv infections in both developing and developed countries.
Pharmaceuticals
Viriom Inc - Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by Sprouts.ai, used by Viriom Inc.
Materialize
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Javascript
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Vue.js
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
TweenMax
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Polyfill
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
PHP
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Employee profile
John Doe
CEO
Samantha Duncan
CTO
Gary Austin
MD
Jonathan Shaw
CMD
Janice May
MD
Janet McDonald
CFO
Viriom Inc - Company Information
Viriom inc. is a commercial and late development stage biotech company developing novel therapies and prevention treatments against hiv and hepatitis b virus (hbv). viriom's pipeline includes: elpida® (elsulfavirine), the best-in-class nnrti that received its first market authorization in 2017; fixed doze combinations with nucleoside reverse transcriptase inhibitors; an innovative extended release weekly oral formulation; and vm1500a - a long acting injectable therapy and pre-exposure prophylaxis. viriom is also developing a highly potent prodrug of the antiviral tenofovir (active component of both vemlidy® and viread®) to treat hiv and hepatitis b patients. viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of hiv and chronic hbv infections in both developing and developed countries.
Pharmaceuticals
Viriom Inc - Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by Sprouts.ai, used by Viriom Inc.
Materialize
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Javascript
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Vue.js
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
TweenMax
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Polyfill
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
PHP
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Employee profile
John Doe
CEO
Samantha Duncan
CTO
Gary Austin
MD
Jonathan Shaw
CMD
Janice May
MD
Janet McDonald
CFO
